首页
数据库
关于我们
联系我们
您当前的位置： 首页 > 数据库
所属年份
2008 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
到
2008 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
检索 清除
手术分类
  • 全部（2447）
  • 腹部手术（342）
  • 胸科手术（70）
  • 血管手术（5）
  • 心脏手术（97）
  • 神经外科（4）
  • 头颈部（35）
  • 骨科（78）
  • 泌尿外科（0）
  • 妇产手术（77）
  • 日间手术（26）
  • 手术室外（28）
  • 创伤和烧伤（0）
  • 非心脏手术（472）
  • 老年（0）
  • 小儿新生儿（189）
  • 特殊患者（42）
  • 未说明手术类型（982）
阶段管理
  • 术前宣教（21）
  • 术前评估（33）
  • 术前用药（15）
  • 术前禁食水（12）
  • 麻醉选择（21）
  • 麻醉用药（10）
  • 术中监测（23）
  • 液体管理（14）
  • 血液保护（3）
  • 体温管理（8）
  • 术后疼痛（62）
  • POD（8）
  • PONV（10）
  • 术后康复（50）
  • 特殊情况（43）
  • 术前肠道准备（9）
排序：
发表时间 阅读量
Array ( [id] => 3175 [catid] => 289 [title] => Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (fifth edition) [thumb] => [keywords] => [description] => [hits] => [uid] => 3 [author] => 甘肃中医院 [status] => 9 [url] => /show/3175.html [link_id] => 0 [tableid] => 0 [inputip] => 106.86.177.165 [inputtime] => 2026-04-14 11:42:49 [updatetime] => 2026-04-14 11:42:49 [displayorder] => 0 [nrjc] => Array ( ) [nrsh] => Array ( ) [xzl] => 0 [dzl] => 0 [wailian] => https://www.ipubmed.cn/Archive/Detail/39880411 [demo_url] => [zjpjff] => GRADE [zjfj] => [tjqd] => [nianfen] => 2025 [guojia] => American Society of Regional Anesthesia & Pain Med [pdf] => [tjyjyw] => [lyyw] => We suggest that a high dose of rivaroxaban be discontinued for at least 72 hours prior to neuraxial block or deep plexus/peripheral block. Consider checking rivaroxaban or aXa activity plasma level if <72 hours. [laiyuan] => 建议高剂量利伐沙班在神经轴阻滞或深丛 / 外周阻滞前至少停药 72 小时；若停药时间不足 72 小时，可考虑检测利伐沙班或抗 Xa 因子活性血浆水平。（证据等级：低，推荐强度：弱推荐） [znzldj] => B [_inputtime] => 1776138169 [_updatetime] => 1776138169 [_nrjc] => [_nrsh] => )
推荐意见
建议高剂量利伐沙班在神经轴阻滞或深丛 / 外周阻滞前至少停药 72 小时；若停药时间不足 72 小时，可考虑检测利伐沙班或抗 Xa 因子活性血浆水平。（证据等级：低，推荐强度：弱推荐）

We suggest that a high dose of rivaroxaban be discontinued for at least 72 hours prior to neuraxial block or deep plexus/peripheral block. Consider checking rivaroxaban or aXa activity plasma level if <72 hours.

证据评价方法：GRADE

指南质量等级：B

年份：2025

国家：American Society of Regional Anesthesia & Pain Med

来源 Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (fifth edition)
原文链接
阅读
Array ( [id] => 3176 [catid] => 289 [title] => Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (fifth edition) [thumb] => [keywords] => [description] => [hits] => [uid] => 3 [author] => 甘肃中医院 [status] => 9 [url] => /show/3176.html [link_id] => 0 [tableid] => 0 [inputip] => 106.86.177.165 [inputtime] => 2026-04-14 11:42:49 [updatetime] => 2026-04-14 11:42:49 [displayorder] => 0 [nrjc] => Array ( ) [nrsh] => Array ( ) [xzl] => 0 [dzl] => 0 [wailian] => https://www.ipubmed.cn/Archive/Detail/39880411 [demo_url] => [zjpjff] => GRADE [zjfj] => [tjqd] => [nianfen] => 2025 [guojia] => American Society of Regional Anesthesia & Pain Med [pdf] => [tjyjyw] => [lyyw] => We suggest that a residual rivaroxaban plasma level <30 ng/mL or a residual aXa activity plasma level ≤0.1 IU/mL is acceptable prior to neuraxial block or deep plexus/peripheral block. [laiyuan] => 神经轴阻滞或深丛 / 外周阻滞前，利伐沙班残余血浆水平 < 30 ng/mL 或残余抗 Xa 因子活性≤0.1 IU/mL 为可接受水平。（证据等级：低，推荐强度：弱推荐） [znzldj] => B [_inputtime] => 1776138169 [_updatetime] => 1776138169 [_nrjc] => [_nrsh] => )
推荐意见
神经轴阻滞或深丛 / 外周阻滞前，利伐沙班残余血浆水平 < 30 ng/mL 或残余抗 Xa 因子活性≤0.1 IU/mL 为可接受水平。（证据等级：低，推荐强度：弱推荐）

We suggest that a residual rivaroxaban plasma level <30 ng/mL or a residual aXa activity plasma level ≤0.1 IU/mL is acceptable prior to neuraxial block or deep plexus/peripheral block.

证据评价方法：GRADE

指南质量等级：B

年份：2025

国家：American Society of Regional Anesthesia & Pain Med

来源 Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (fifth edition)
原文链接
阅读
Array ( [id] => 3177 [catid] => 303 [title] => Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (fifth edition) [thumb] => [keywords] => [description] => [hits] => [uid] => 3 [author] => 甘肃中医院 [status] => 9 [url] => /show/3177.html [link_id] => 0 [tableid] => 0 [inputip] => 106.86.177.165 [inputtime] => 2026-04-14 11:42:49 [updatetime] => 2026-04-14 11:42:49 [displayorder] => 0 [nrjc] => Array ( ) [nrsh] => Array ( ) [xzl] => 0 [dzl] => 0 [wailian] => https://www.ipubmed.cn/Archive/Detail/39880411 [demo_url] => [zjpjff] => GRADE [zjfj] => [tjqd] => [nianfen] => 2025 [guojia] => American Society of Regional Anesthesia & Pain Med [pdf] => [tjyjyw] => [lyyw] => We suggest that needle placement/catheter removal occurs at least 24 hours prior to the first postoperative dose (high dose). [laiyuan] => 高剂量给利伐沙班场景下，穿刺 / 拔管应在术后首次给药前至少 24 小时进行。（证据等级：低，推荐强度：弱推荐） [znzldj] => B [_inputtime] => 1776138169 [_updatetime] => 1776138169 [_nrjc] => [_nrsh] => )
推荐意见
高剂量给利伐沙班场景下，穿刺 / 拔管应在术后首次给药前至少 24 小时进行。（证据等级：低，推荐强度：弱推荐）

We suggest that needle placement/catheter removal occurs at least 24 hours prior to the first postoperative dose (high dose).

证据评价方法：GRADE

指南质量等级：B

年份：2025

国家：American Society of Regional Anesthesia & Pain Med

来源 Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (fifth edition)
原文链接
阅读
Array ( [id] => 3178 [catid] => 303 [title] => Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (fifth edition) [thumb] => [keywords] => [description] => [hits] => [uid] => 3 [author] => 甘肃中医院 [status] => 9 [url] => /show/3178.html [link_id] => 0 [tableid] => 0 [inputip] => 106.86.177.165 [inputtime] => 2026-04-14 11:42:49 [updatetime] => 2026-04-14 11:42:49 [displayorder] => 0 [nrjc] => Array ( ) [nrsh] => Array ( ) [xzl] => 0 [dzl] => 0 [wailian] => https://www.ipubmed.cn/Archive/Detail/39880411 [demo_url] => [zjpjff] => GRADE [zjfj] => [tjqd] => [nianfen] => 2025 [guojia] => American Society of Regional Anesthesia & Pain Med [pdf] => [tjyjyw] => [lyyw] => With the unanticipated administration of high dose of rivaroxaban with a neuraxial catheter in situ, we suggest that rivaroxaban dosing be withheld for at least 72 hours, or a residual rivaroxaban plasma level <30 ng/mL or a residual aXa activity plasma level ≤0.1 IU/mL before the catheter is removed. [laiyuan] => 若神经轴导管在位时意外使用了高剂量利伐沙班，建议停药至少 72 小时，或检测残余血浆水平 < 30 ng/mL、残余抗 Xa 因子活性≤0.1 IU/mL 后再拔管。（证据等级：低，推荐强度：弱推荐） [znzldj] => B [_inputtime] => 1776138169 [_updatetime] => 1776138169 [_nrjc] => [_nrsh] => )
推荐意见
若神经轴导管在位时意外使用了高剂量利伐沙班，建议停药至少 72 小时，或检测残余血浆水平 < 30 ng/mL、残余抗 Xa 因子活性≤0.1 IU/mL 后再拔管。（证据等级：低，推荐强度：弱推荐）

With the unanticipated administration of high dose of rivaroxaban with a neuraxial catheter in situ, we suggest that rivaroxaban dosing be withheld for at least 72 hours, or a residual rivaroxaban plasma level <30 ng/mL or a residual aXa activity plasma level ≤0.1 IU/mL before the catheter is removed.

证据评价方法：GRADE

指南质量等级：B

年份：2025

国家：American Society of Regional Anesthesia & Pain Med

来源 Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (fifth edition)
原文链接
阅读
Array ( [id] => 3179 [catid] => 289 [title] => Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (fifth edition) [thumb] => [keywords] => [description] => [hits] => [uid] => 3 [author] => 甘肃中医院 [status] => 9 [url] => /show/3179.html [link_id] => 0 [tableid] => 0 [inputip] => 106.86.177.165 [inputtime] => 2026-04-14 11:42:49 [updatetime] => 2026-04-14 11:42:49 [displayorder] => 0 [nrjc] => Array ( ) [nrsh] => Array ( ) [xzl] => 0 [dzl] => 0 [wailian] => https://www.ipubmed.cn/Archive/Detail/39880411 [demo_url] => [zjpjff] => GRADE [zjfj] => [tjqd] => [nianfen] => 2025 [guojia] => American Society of Regional Anesthesia & Pain Med [pdf] => [tjyjyw] => [lyyw] => We suggest that a low dose of rivaroxaban be discontinued for at least 24 hours (30 hours if CrCl<30 mL/min) prior to neuraxial block or deep plexus/peripheral block. Consider checking rivaroxaban or aXa activity plasma level if <24 hours. [laiyuan] => 建议低剂量利伐沙班在神经轴阻滞或深丛 / 外周阻滞前至少停药 24 小时（肌酐清除率 < 30 mL/min 时停药 30 小时）；若停药时间不足 24 小时，可考虑检测利伐沙班或抗 Xa 因子活性血浆水平。（证据等级：低，推荐强度：弱推荐） [znzldj] => B [_inputtime] => 1776138169 [_updatetime] => 1776138169 [_nrjc] => [_nrsh] => )
推荐意见
建议低剂量利伐沙班在神经轴阻滞或深丛 / 外周阻滞前至少停药 24 小时（肌酐清除率 < 30 mL/min 时停药 30 小时）；若停药时间不足 24 小时，可考虑检测利伐沙班或抗 Xa 因子活性血浆水平。（证据等级：低，推荐强度：弱推荐）

We suggest that a low dose of rivaroxaban be discontinued for at least 24 hours (30 hours if CrCl<30 mL/min) prior to neuraxial block or deep plexus/peripheral block. Consider checking rivaroxaban or aXa activity plasma level if <24 hours.

证据评价方法：GRADE

指南质量等级：B

年份：2025

国家：American Society of Regional Anesthesia & Pain Med

来源 Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (fifth edition)
原文链接
阅读
Array ( [id] => 3180 [catid] => 289 [title] => Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (fifth edition) [thumb] => [keywords] => [description] => [hits] => [uid] => 3 [author] => 甘肃中医院 [status] => 9 [url] => /show/3180.html [link_id] => 0 [tableid] => 0 [inputip] => 106.86.177.165 [inputtime] => 2026-04-14 11:42:49 [updatetime] => 2026-04-14 11:42:49 [displayorder] => 0 [nrjc] => Array ( ) [nrsh] => Array ( ) [xzl] => 0 [dzl] => 0 [wailian] => https://www.ipubmed.cn/Archive/Detail/39880411 [demo_url] => [zjpjff] => GRADE [zjfj] => [tjqd] => [nianfen] => 2025 [guojia] => American Society of Regional Anesthesia & Pain Med [pdf] => [tjyjyw] => [lyyw] => We suggest that needle placement/catheter removal occurs at least 6 hours prior to the first postoperative dose (low dose). [laiyuan] => 低剂量给利伐沙班场景下，穿刺 / 拔管应在术后首次给药前至少 6 小时进行。（证据等级：低，推荐强度：弱推荐） [znzldj] => B [_inputtime] => 1776138169 [_updatetime] => 1776138169 [_nrjc] => [_nrsh] => )
推荐意见
低剂量给利伐沙班场景下，穿刺 / 拔管应在术后首次给药前至少 6 小时进行。（证据等级：低，推荐强度：弱推荐）

We suggest that needle placement/catheter removal occurs at least 6 hours prior to the first postoperative dose (low dose).

证据评价方法：GRADE

指南质量等级：B

年份：2025

国家：American Society of Regional Anesthesia & Pain Med

来源 Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (fifth edition)
原文链接
阅读
Array ( [id] => 3181 [catid] => 303 [title] => Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (fifth edition) [thumb] => [keywords] => [description] => [hits] => [uid] => 3 [author] => 甘肃中医院 [status] => 9 [url] => /show/3181.html [link_id] => 0 [tableid] => 0 [inputip] => 106.86.177.165 [inputtime] => 2026-04-14 11:42:49 [updatetime] => 2026-04-14 11:42:49 [displayorder] => 0 [nrjc] => Array ( ) [nrsh] => Array ( ) [xzl] => 0 [dzl] => 0 [wailian] => https://www.ipubmed.cn/Archive/Detail/39880411 [demo_url] => [zjpjff] => GRADE [zjfj] => [tjqd] => [nianfen] => 2025 [guojia] => American Society of Regional Anesthesia & Pain Med [pdf] => [tjyjyw] => [lyyw] => With the unanticipated administration of low dose of rivaroxaban with a neuraxial catheter in situ, we suggest that rivaroxaban dosing be withheld for at least 24 hours (30 hours if CrCl<30 mL/min), or a residual rivaroxaban plasma level <30 ng/mL or a residual aXa activity plasma level ≤0.1 IU/mL before the catheter is removed. [laiyuan] => 若神经轴导管在位时意外使用了低剂量利伐沙班，建议停药至少 24 小时（肌酐清除率 < 30 mL/min 时停药 30 小时），或检测残余血浆水平 < 30 ng/mL、残余抗 Xa 因子活性≤0.1 IU/mL 后再拔管。（证据等级：低，推荐强度：弱推荐） [znzldj] => B [_inputtime] => 1776138169 [_updatetime] => 1776138169 [_nrjc] => [_nrsh] => )
推荐意见
若神经轴导管在位时意外使用了低剂量利伐沙班，建议停药至少 24 小时（肌酐清除率 < 30 mL/min 时停药 30 小时），或检测残余血浆水平 < 30 ng/mL、残余抗 Xa 因子活性≤0.1 IU/mL 后再拔管。（证据等级：低，推荐强度：弱推荐）

With the unanticipated administration of low dose of rivaroxaban with a neuraxial catheter in situ, we suggest that rivaroxaban dosing be withheld for at least 24 hours (30 hours if CrCl<30 mL/min), or a residual rivaroxaban plasma level <30 ng/mL or a residual aXa activity plasma level ≤0.1 IU/mL before the catheter is removed.

证据评价方法：GRADE

指南质量等级：B

年份：2025

国家：American Society of Regional Anesthesia & Pain Med

来源 Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (fifth edition)
原文链接
阅读
Array ( [id] => 3182 [catid] => 303 [title] => Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (fifth edition) [thumb] => [keywords] => [description] => [hits] => [uid] => 3 [author] => 甘肃中医院 [status] => 9 [url] => /show/3182.html [link_id] => 0 [tableid] => 0 [inputip] => 106.86.177.165 [inputtime] => 2026-04-14 11:42:49 [updatetime] => 2026-04-14 11:42:49 [displayorder] => 0 [nrjc] => Array ( ) [nrsh] => Array ( ) [xzl] => 0 [dzl] => 0 [wailian] => https://www.ipubmed.cn/Archive/Detail/39880411 [demo_url] => [zjpjff] => GRADE [zjfj] => [tjqd] => [nianfen] => 2025 [guojia] => American Society of Regional Anesthesia & Pain Med [pdf] => [tjyjyw] => [lyyw] => We suggest that a high dose of dabigatran be discontinued for at least 72 hours in patients with a CrCl ≥50 mL/min prior to neuraxial block or deep plexus/peripheral block. Consider checking dabigatran plasma level if <72 hours. [laiyuan] => 对于肌酐清除率≥50 mL/min 的患者，高剂量达比加群在神经轴阻滞或深丛 / 外周阻滞前至少停药 72 小时；若停药时间不足 72 小时，可考虑检测达比加群血浆水平。（证据等级：低，推荐强度：弱推荐） [znzldj] => B [_inputtime] => 1776138169 [_updatetime] => 1776138169 [_nrjc] => [_nrsh] => )
推荐意见
对于肌酐清除率≥50 mL/min 的患者，高剂量达比加群在神经轴阻滞或深丛 / 外周阻滞前至少停药 72 小时；若停药时间不足 72 小时，可考虑检测达比加群血浆水平。（证据等级：低，推荐强度：弱推荐）

We suggest that a high dose of dabigatran be discontinued for at least 72 hours in patients with a CrCl ≥50 mL/min prior to neuraxial block or deep plexus/peripheral block. Consider checking dabigatran plasma level if <72 hours.

证据评价方法：GRADE

指南质量等级：B

年份：2025

国家：American Society of Regional Anesthesia & Pain Med

来源 Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (fifth edition)
原文链接
阅读
Array ( [id] => 3183 [catid] => 289 [title] => Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (fifth edition) [thumb] => [keywords] => [description] => [hits] => [uid] => 3 [author] => 甘肃中医院 [status] => 9 [url] => /show/3183.html [link_id] => 0 [tableid] => 0 [inputip] => 106.86.177.165 [inputtime] => 2026-04-14 11:42:49 [updatetime] => 2026-04-14 11:42:49 [displayorder] => 0 [nrjc] => Array ( ) [nrsh] => Array ( ) [xzl] => 0 [dzl] => 0 [wailian] => https://www.ipubmed.cn/Archive/Detail/39880411 [demo_url] => [zjpjff] => GRADE [zjfj] => [tjqd] => [nianfen] => 2025 [guojia] => American Society of Regional Anesthesia & Pain Med [pdf] => [tjyjyw] => [lyyw] => We suggest that a high dose of dabigatran be discontinued for 120 hours in patients with a CrCl 30–49 mL/min prior to neuraxial block or deep plexus/peripheral block. Consider checking dabigatran plasma level if <120 hours. [laiyuan] => 对于肌酐清除率 30-49 mL/min 的患者，高剂量达比加群在神经轴阻滞或深丛 / 外周阻滞前停药 120 小时；若停药时间不足 120 小时，可考虑检测达比加群血浆水平。（证据等级：低，推荐强度：弱推荐） [znzldj] => B [_inputtime] => 1776138169 [_updatetime] => 1776138169 [_nrjc] => [_nrsh] => )
推荐意见
对于肌酐清除率 30-49 mL/min 的患者，高剂量达比加群在神经轴阻滞或深丛 / 外周阻滞前停药 120 小时；若停药时间不足 120 小时，可考虑检测达比加群血浆水平。（证据等级：低，推荐强度：弱推荐）

We suggest that a high dose of dabigatran be discontinued for 120 hours in patients with a CrCl 30–49 mL/min prior to neuraxial block or deep plexus/peripheral block. Consider checking dabigatran plasma level if <120 hours.

证据评价方法：GRADE

指南质量等级：B

年份：2025

国家：American Society of Regional Anesthesia & Pain Med

来源 Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (fifth edition)
原文链接
阅读
Array ( [id] => 3184 [catid] => 290 [title] => Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (fifth edition) [thumb] => [keywords] => [description] => [hits] => [uid] => 3 [author] => 甘肃中医院 [status] => 9 [url] => /show/3184.html [link_id] => 0 [tableid] => 0 [inputip] => 106.86.177.165 [inputtime] => 2026-04-14 11:42:49 [updatetime] => 2026-04-14 11:42:49 [displayorder] => 0 [nrjc] => Array ( ) [nrsh] => Array ( ) [xzl] => 0 [dzl] => 0 [wailian] => https://www.ipubmed.cn/Archive/Detail/39880411 [demo_url] => [zjpjff] => GRADE [zjfj] => [tjqd] => [nianfen] => 2025 [guojia] => American Society of Regional Anesthesia & Pain Med [pdf] => [tjyjyw] => [lyyw] => We suggest against the performance of neuraxial or deep plexus/peripheral blocks in patients with a CrCl<30 mL/min unless a dabigatran plasma level is obtained and <30 ng/mL. [laiyuan] => 不建议对肌酐清除率 < 30 mL/min 的患者进行神经轴或深丛 / 外周阻滞，除非检测达比加群血浆水平 < 30 ng/mL。（证据等级：低，推荐强度：弱推荐） [znzldj] => B [_inputtime] => 1776138169 [_updatetime] => 1776138169 [_nrjc] => [_nrsh] => )
推荐意见
不建议对肌酐清除率 < 30 mL/min 的患者进行神经轴或深丛 / 外周阻滞，除非检测达比加群血浆水平 < 30 ng/mL。（证据等级：低，推荐强度：弱推荐）

We suggest against the performance of neuraxial or deep plexus/peripheral blocks in patients with a CrCl<30 mL/min unless a dabigatran plasma level is obtained and <30 ng/mL.

证据评价方法：GRADE

指南质量等级：B

年份：2025

国家：American Society of Regional Anesthesia & Pain Med

来源 Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (fifth edition)
原文链接
阅读

地址：甘肃省兰州市七里河区瓜州路418号

邮编：730050

电话：0931-2687109

商务合作热线：0931-2687106

备案号：陇ICP备17005383号-1 联网备案号：62010302000288

技术支持：瑞秀科技